PEARL: Postmenopausal evaluation and risk-reduction with lasofoxifene

Trial Profile

PEARL: Postmenopausal evaluation and risk-reduction with lasofoxifene

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Lasofoxifene (Primary)
  • Indications Bone resorption; Breast cancer; Cardiovascular disorders; Fracture; Postmenopausal osteoporosis
  • Focus Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms PEARL
  • Sponsors Ligand Pharmaceuticals
  • Most Recent Events

    • 11 Oct 2010 Cardiovascular outcomes published in Circulation.
    • 25 Feb 2010 Results published in New England Journal of Medicine.
    • 11 Dec 2008 Results were presented at the 31st Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top